Last reviewed · How we verify
FSH-R
FSH-R is a follicle-stimulating hormone receptor agonist that stimulates ovarian follicle development and maturation for reproductive purposes.
FSH-R is a follicle-stimulating hormone receptor agonist that stimulates ovarian follicle development and maturation for reproductive purposes. Used for Infertility in women undergoing assisted reproductive technology (ART), Ovulation induction.
At a glance
| Generic name | FSH-R |
|---|---|
| Sponsor | Insemine Humen Reproduction Centre |
| Drug class | FSH receptor agonist |
| Target | FSH-R (Follicle-Stimulating Hormone Receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 2 |
Mechanism of action
FSH-R activates the follicle-stimulating hormone receptor on granulosa cells of ovarian follicles, promoting follicle growth, estrogen production, and oocyte maturation. This mechanism is used to enhance fertility outcomes in assisted reproductive technology by increasing the number of mature oocytes available for fertilization.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART)
- Ovulation induction
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal discomfort
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (NA)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (PHASE1)
- Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)
- Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells (PHASE1)
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- Inhibin B/AFC Ratio for Ovarian Response
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FSH-R CI brief — competitive landscape report
- FSH-R updates RSS · CI watch RSS
- Insemine Humen Reproduction Centre portfolio CI